BioInvent and Transgene report encouraging Phase 1/2a trial results for BT-001 oncolytic virus with Merck's KEYTRUDA, showing a favorable safety profile and improved response rates.

BioInvent and Transgene reported encouraging early Phase 1/2a trial results for BT-001, an oncolytic virus combined with Merck's KEYTRUDA (pembrolizumab). The therapy demonstrated a favorable safety profile, with no dose-limiting toxicities. In monotherapy, 4 of 18 patients showed stable disease, while 2 of 6 patients had partial responses when combined with pembrolizumab. Findings will be presented at the ESMO Annual Meeting in September 2024.

September 09, 2024
3 Articles